After a mean follow-up of @ months , the primary endpoint occurred in @ patients ( @ % ) in the eplerenone group and in @ patients ( @ % ) in the placebo group -LSB- adjusted hazard ratio ( HR ) , @ ; @ % confidence interval ( CI ) , @-@ @ ; P < @ -RSB- .